Link to this page
Physician Data Query
Last uploaded:
August 28, 2024
Jump to:
| Preferred Name | alogliptin | |
| Synonyms |
benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]- |
|
| Definitions |
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76906" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76906" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000733686 |
|
| altLabel |
benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]-
|
|
| CAS Registry |
850649-61-5
|
|
| cui |
C1958126
|
|
| DATE FIRST PUBLISHED |
2012-05-04
|
|
| Date last modified |
2012-05-04
|
|
| definition |
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C76906" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C76906" NCI Thesaurus)
|
|
| NCI ID |
C76906
|
|
| notation |
CDR0000733686
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
alogliptin
|
|
| tui |
T109 T121
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping